Insalud Takes More Cost Control Measures

31 July 1994

Insalud in Spain is implementing more measures to control pharmaceutical expenditure. The national health institute service is sending out letters to Spain's 13,000 general practitioners telling them how much their individual prescribing habits cost the institute.

Doctors each have a number on their prescriptions which allows the Health Ministry to track their prescribing. This tracking method was started up in 1993 as a pilot scheme and forms part of the information system for rational drug use, according to comments to Spanish newspaper Cinco Dias by an Insalud spokesperson.

The spokesperson said that scheme is not designed to track costs but to help the identification of therapeutic profiles. However, many doctors have commented that the information has made them more aware of expenditure and they are beginning to prescribe cheaper products.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight